Studies of the immune response in breast cancer. by Roberts, M. M. & Bass, E. M.
ABSTRACTS OF MEMBERS PROFFERED PAPERS 77
ANDROGEN METABOLISM IN
HUMAN NEOPLASTIC AND NORMAL
BREAST TISSUE. W. R. MILLER, A.
BOYD, J. TELFORD, A. A. SHIVAS and
A. P. M. FORREST. Department of Clinical
Surgery, Royal Infirmary, Edinburgh.
Human breast cancer can transform
certain steroids into physiologically active
hormones (Adams and Wong, J. Endocr.,
1968, 41, 41; Jones et al., Biochem. J., 1970,
116, 916). It therefore has the potential to
produce a local hormonal environment which
may influence tumour growth. The aim of
this study was to determine whether this
potential w%as shared by human benign and
normal breast tissue. Slices of three breast
cancers, two fibroadenomata, one fibro-
adenosis and normal breast tissue associated
with each w-ere incubated in vitro wvith
[3H]-dehydroepiandrosterone and [14C]-testo-
sterone. The transformation of dehydro-
epiandrosterone to testosterone and testo-
sterone to 5-dihydrotestosterone were mea-
sured. Each type of tissue was capable of
performing'these conversions, although some
quantitative differences were evident between
tissue groups. Nevertheless, it is empha-
sized that the potentiai for para-endocrine
activity is shared by malignant and benign
tumours of the breast and normal breast
tissue.
STEROID SULPHATION IN VITRO
BY HUMAN BREAST CANCER
TISSUE. E. MELVILLE and H. BRAUNS-
BERG. M.R.C. Clinical Endocrinology Unit,
Edinburgh.
The production of (lehydroepiandro-
sterone (DHAS) and oestradiol sulphate
(E2S) was studied in a subcellular fraction
prepared from each of 69 primary breast
tumours. Steroid sulphation was measured
by the method of Dao and Libby (J. cliii.
Endocr., 1968, 28, 1431) with minor modifica-
tions. The quantity of each steroid sulphate
produced by 25 mg wet, wseight tissue during
incubation was calculated. Only 40 of 69
tumours were found to effect steroid sulpha-
tion. Tumours froin premenopausal women
produced significantly more (P = 0.01) of
each steroid sulphate than tumours from
post-menopausal women. It, has been re-
ported by Dao and Libby (Surgery, 1969, 66,
162) that, a high ratio of DHAS production to
E2S production can be associated with a
good clinical response to adrenalectomy.
The ratio of DHAS production to E2S pro-
duction was in the range 0-8-1-2 for pre-
menopausal women (n = 9) and in the range
0 4 to 3 8 for post-menopausal women
(n = 23).
STUDIES OF THE IMMUNE RE-
SPONSE IN BREAST CANCER. M. M.
ROBERTS, E. M. BASS (introduced by
A. P. M. FORREST). Department of Clinical
Surgery, Royal Infirmary, Edinburgh.
Protein extracts have been prepared
from 55 malignant, 20 benign tumours of the
breast and from " normal " tissue in 17
cancer bearing breasts. Total protein and
immunoglobulin concentrations have been
measured in all extracts by the methods of
Lowry and Mancini respectively (Lowry et al.,
J. Biol. Chem., 1951, 193, 365; Mancini et al.,
Immunochemistry, 1965, 2, 235). A stan-
dardized dose has been used for skin testing
30 patients with their own tissue extracts.
A search was made for precipitating anti-
bodies to tumour extract in the serum of
45 patients by the Ouchterlony double
diffusion technique (Ouchterlony, Prog.
Allergy, 1958, V, 1).
The mean protein levels in malignant
tumours (1-36 mg/ml) were slightly lower
than in benign and normal tissues (1-66 mg/
ml). Tissue immunoglobulin levels were
significantly reduced in cancer tissue com-
pared with normal and benign tissues, except
for IgM which was consistently higher in the
malignant tumours. Delayed hypersensi-
tivity reactions were observed in 5000 of
patients tested with their own tumour
extracts, but were also observed in response
to normal tissue and in patients tested with
their ow-n benign tumours. Precipitating
antibodies in the serum occurred in 110% of
cancer patients, but in none of the patients
with benign disease of the breast.
CELLULAR IMMUNITY IN HUMAN
MALIGNANT MELANOMA AND
MELANOMA HISTOLOGY. D. E.
CAMERON-MOWAT, A. J. COCHRAN, R. M.
GRANT, C. E. THOMAS, R. M. MACKIE and
W. G. S. SPILG. University Departments of
Pathology and Dermatology, University of
Glasgow.